MONOPRIL-HCT
LOE ApproachingNDAORALTABLET
Approved
Nov 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 15h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MONOPRIL-HCT is a fixed-dose combination oral tablet approved in 1994 combining an ACE inhibitor with a thiazide diuretic. The drug is indicated for hypertension management and represents a small-molecule therapeutic combination. It is positioned as a convenience therapy for blood pressure control in patients requiring dual antihypertensive agents.
LOE Approaching
Moderate competitive pressure (30/100) indicates a mature, contested market with limited growth prospects and likely right-sizing of commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining a MONOPRIL-HCT team offers stability in a mature, well-understood therapeutic area but limited career acceleration or innovation exposure. This role suits professionals seeking to consolidate expertise in hypertension management and generic transition strategies rather than pursue breakthrough drug development.
Brand ManagerMarket Access Manager
Worked on MONOPRIL-HCT at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.